Cavalry Fund I LP 61 Kinderkamack Road Woodcliff Lake, NJ 07677 December 31, 2018  VIA EMAIL:paul@parallaxcare.com  Parallax Health Sciences, Inc. 1327 Ocean Avenue, Suite B Santa Monica CA 90401 Attention: Paul R. Arena  Re:Amendment to Promissory Note  Dear Mr. Arena:  This letter agreement (this “Agreement”) by and between Parallax Health Science, Inc. (the “Company”) and Cavalry Fund I LP (“Cavalry”) acknowledges that effective November 14, 2018, the parties hereto agree to amend the terms of that certain convertible promissory note (the “Note”) issued by the Company to Cavalry on June 14, 2018 (the “Issuance Date”) in the initial principal amount of $250,000.00 (the “Principal”). Pursuant to the terms of the Note and the agreements thereto, the Note is currently in default. The parties hereto agree to extend the Maturity Date of the Note to February 28, 2019 (the “Amended Maturity Date”) in exchange for the Company agreeing to increase the principal amount of the Note to $322,411.86 (the “Amended Principal”). Interest from the Issuance Date until the date of this Agreement shall be calculated based on the Principal and interest from the date of this Agreement until the amended Maturity Date shall be calculated based on the Amended Principal. The parties hereto agree that the issuance of a Debenture (the “Amended Debenture”), issued pursuant to the terms of this Agreement, shall constitute an exchange of securities pursuant to pursuant to Section 3(a)(9) of the Securities Act of 1933 and $250,000.00 of the Amended Principal and interest accrued monthly shall tack back to the Issuance Date for purposes of Rule 144 thereunder. In all other respects the parties hereto ratify and affirm the terms of the Amended Debenture. Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument. Any terms not defined in this Agreement shall have the same meaning as in the Amended Debenture. Please execute below signifying your consent to this Agreement.        BN 35286576v1     Sincerely yours,  Cavalry Fund I LP By: Cavalry Fund I Management LLC Its: General Partner  By:/s/ Thomas P. Walsh Name: Thomas P. Walsh Title: Manager   We hereby agree to the foregoing: PARALLAX HEALTH SCIENCES, INC.    By:/s/ Paul R. Arena Name: Paul R. Arena Title: Chief Executive Officer         M:\10401\Private Placements\Parallax\Parallax Letter Agreement to amend note. - 11-27-18.docx/csb                    BN 35286576v1     DiamondRock, LLC 715 N. Kilkea Drive Los Angeles, CA 90046 December 31, 2018  VIA EMAIL:paul@parallaxcare.com  Parallax Health Sciences, Inc. 1327 Ocean Avenue, Suite B Santa Monica CA 90401 Attention: Paul R. Arena  Re:Amendment to Promissory Note  Dear Mr. Arena:  This letter agreement (this “Agreement”) by and between Parallax Health Science, Inc. (the “Company”) and DiamondRock, LLC (“DiamondRock”) acknowledges that effective November 14, 2018, the parties hereto agree to amend the terms of those certain convertible promissory notes (the “Notes”) issued by the Company to DiamondRock on May 1, 2018, May 29, 2018 and June 14, 2018 (the “Issuance Date”) in the aggregate initial principal amount of $116,667.00 (the “Principal”). Pursuant to the terms of the Note and the agreements thereto, the  Note is currently in default. The parties hereto agree to extend the Maturity Date of the Note to February 28, 2019 (the “Amended Maturity Date”) in exchange for the Company agreeing to increase the principal amount of the Note to $150,194.92 (the “Amended Principal”). Interest from the Issuance Date until the date of this Agreement shall be calculated based on the Principal and interest from the date of this Agreement until the amended Maturity Date shall be calculated based on the Amended Principal. The parties hereto agree that the issuance of a Debenture (the “Amended Debenture”), issued pursuant to the terms of this Agreement, shall constitute an exchange of securities pursuant to pursuant to Section 3(a)(9) of the Securities Act of 1933 and $116,667.00 of the Amended Principal and interest accrued monthly shall tack back to the Issuance Date for purposes of Rule 144 thereunder. In all other respects the parties hereto ratify and affirm the terms of the Amended Debenture. Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument. Any terms not defined in this Agreement shall have the same meaning as in the Amended Debenture. Please execute below signifying your consent to this Agreement.        BN 35286553v1     Sincerely yours,  DiamondRock, LLC By: Neil Rock Its: Chief Executive Officer  By: /s/ Neil Rock Name: Neil Rock Title: Chief Executive Officer    We hereby agree to the foregoing: PARALLAX HEALTH SCIENCES, INC.    By:/s/ Paul R. Arena Name: Paul R. Arena Title: Chief Executive Officer                            BN 35286553v1    The Corbran, LLC 55 Lane Road, Suite 430 Fairfield, NJ 07004 December 31, 2018  VIA EMAIL:paul@parallaxcare.com  Parallax Health Sciences, Inc. 1327 Ocean Avenue, Suite B Santa Monica CA 90401 Attention: Paul R. Arena  Re:Amendment to Promissory Note  Dear Mr. Arena:  This letter agreement (this “Agreement”) by and between Parallax Health Science, Inc. (the “Company”) and The Corbran, LLC (“TCL”) acknowledges that effective November 14, 2018, the parties hereto agree to amend the terms of those certain convertible promissory notes (the “Notes”) issued by the Company to TCL on April 24, 2018 and June 14, 2018 (the “Issuance Date”) in the aggregate initial principal amount of $58,333.00 (the “Principal”). Pursuant to the terms of the Note and the agreements thereto, the Note is currently in default. The parties hereto agree to extend the Maturity Date of the Note by 120 days (the “Amended Maturity Date”) in exchange for the Company agreeing to increase the principal amount of the Note to $73,879.62 (the “Amended Principal”). Interest from the Issuance Date until the date of this Agreement shall be calculated based on the Principal and interest from the date of this Agreement until the amended Maturity Date shall be calculated based on the Amended Principal. The parties hereto agree that the issuance of a Debenture (the “Amended Debenture”), issued pursuant to the terms of this Agreement, shall constitute an exchange of securities pursuant to pursuant to Section 3(a)(9) of the Securities Act of 1933 and $58,333.00 of the Amended Principal and interest accrued monthly shall tack back to the Issuance Date for purposes of Rule 144 thereunder. In all other respects the parties hereto ratify and affirm the terms of the Amended Debenture. Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument. Any terms not defined in this Agreement shall have the same meaning as in the Amended Debenture. Please execute below signifying your consent to this Agreement.        BN 35285935v1     Sincerely yours,  The Corbran, LLC By: Richard Rosenblum Its: Chief Executive Officer  By: /s/ Richard Rosenblum Name: Richard Rosenblum Title: Chief Executive Officer   We hereby agree to the foregoing: PARALLAX HEALTH SCIENCES, INC.    By:/s/ Paul R. Arena Name: Paul R. Arena Title: Chief Executive Officer                            BN 35285935v1    Digital Power Lending, LLC 201 Shipyard Way, Suite E Newport Beach, CA 92663 December 31, 2018  VIA EMAIL:paul@parallaxcare.com  Parallax Health Sciences, Inc. 1327 Ocean Avenue, Suite B Santa Monica CA 90401 Attention: Paul R. Arena  Re:Amendment to Promissory Note  Dear Mr. Arena:  This letter agreement (this “Agreement”) by and between Parallax Health Science, Inc. (the “Company”) and Digital Power Lending, LLC (“DPL”) acknowledges that effective November 14, 2018, the parties hereto agree to amend the terms of those certain convertible promissory notes (the “Notes”) issued by the Company to DPL on April 24, 2018 and June 14, 2018 (the “Issuance Date”) in the aggregate initial principal amount of $175,000.00 (the “Principal”). Pursuant to the terms of the Note and the agreements thereto, the Note is currently in default. The parties hereto agree to extend the Maturity Date of the Note to February 28, 2019 (the “Amended Maturity Date”) in exchange for the Company agreeing to increase the principal amount of the Note to $221,640.96 (the “Amended Principal”). Interest from the Issuance Date until the date of this Agreement shall be calculated based on the Principal and interest from the date of this Agreement until the amended Maturity Date shall be calculated based on the Amended Principal. The parties hereto agree that the issuance of a Debenture (the “Amended Debenture”), issued pursuant to the terms of this Agreement, shall constitute an exchange of securities pursuant to pursuant to Section 3(a)(9) of the Securities Act of 1933 and $175,000.00 of the Amended Principal and interest accrued monthly shall tack back to the Issuance Date for purposes of Rule 144 thereunder. In all other respects the parties hereto ratify and affirm the terms of the Amended Debenture. Any number of counterparts of this Agreement may be signed and delivered, each of which shall be considered an original and all of which, together, shall constitute one and the same instrument. Any terms not defined in this Agreement shall have the same meaning as in the Amended Debenture. Please execute below signifying your consent to this Agreement.        BN 35286568v1     Sincerely yours,  Digital Power Lending, LLC By: William Corbett Its: President    By: /s/ William Corbett Name: William Corbett Title: President  We hereby agree to the foregoing: PARALLAX HEALTH SCIENCES, INC.    By:/s/ Paul R. Arena Name: Paul R. Arena Title: Chief Executive Officer                            BN 35286568v1